Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15637262 | 0.80 | ALDH1A1 (0.55) | ALDH1A1KDM4EDNM1MEN1KMT2A | |
| SCHEMBL10892321 | 0.78 | HDAC3 (0.53) | ALDH1A1KDM4EDNM1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL11664988 | 0.75 | TDP1 (0.54) | ALDH1A1KDM4ELMNADNM1MEN1 | |
| Hydrogen Sulfide SCHEMBL28016697 | 0.75 | ALDH1A1 (0.61) | ALDH1A1KDM4ELMNAMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7853055 | 0.74 | MEN1 (0.49) | ALDH1A1KDM4EDNM1MEN1KMT2A | |
| SCHEMBL16353097 | 0.74 | ALDH1A1 (0.54) | ALDH1A1DNM1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5963139 | 0.74 | DNM1 (0.67) | ALDH1A1KDM4ELMNADNM1MEN1 | |
| SCHEMBL162806 | 0.74 | HDAC1 (0.62) | ALDH1A1KDM4ELMNACA12CA7 | |
| SCHEMBL16353101 | 0.74 | TDP1 (0.50) | ALDH1A1LMNADNM1MEN1KMT2A | |
| SCHEMBL13702211 | 0.73 | ALDH1A1 (0.62) | ALDH1A1KDM4ELMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3972698-B1 | ORAL COMPOSITIONS AND METHODS OF USE | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-02-12 | — | — | EP | disclosed |
| EP-3463584-B1 | THERAPEUTIC DENTAL PASTES AND THE APPLICATION THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230293393-A1 | NATURAL TOOTH POWDER TABLETS | MCCORMICK LINDSAY (US) | 2023-09-21 | — | — | US | disclosed |
| US-11701306-B2 | Natural tooth powder tablets | MCCORMICK LINDSAY (US) | 2023-07-18 | — | — | US | disclosed |
| US-11696879-B2 | Therapeutic dental pastes and related methods and kits | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-07-11 | — | — | US | disclosed |
| US-20220211603-A1 | Oral Compositions And Methods Of Use | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2022-07-07 | — | — | US | disclosed |
| US-20220192953-A1 | Oral Compositions And Methods Of Use | 3M INNOVATIVE PROPERTIES COMPANY | 2022-06-23 | — | — | US | disclosed |
| EP-3972698-A1 | ORAL COMPOSITIONS AND METHODS OF USE | 3M Innovative Properties Company (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3972557-A1 | ORAL COMPOSITIONS AND METHODS OF USE | 3M Innovative Properties Company (US) | 2022-03-30 | — | — | EP | disclosed |
| CN-113840635-A | Oral compositions and methods of use | 3M创新有限公司 | 2021-12-24 | — | — | CN | disclosed |
| EP-0249398-A2 | Oral compositions | THE PROCTER & GAMBLE COMPANY (US) | 1987-12-16 | — | — | EP | disclosed |
| US-4684518-A | ANTICALCULUS, PYROPHOSPHATE AND FLUORIDE | THE PROCTER & GAMBLE COMPANY (US) | 1987-08-04 | — | — | US | disclosed |
| US-4590066-A | DENTRIFRICE CONTAINING PYROPHOSPHATES | THE PROCTER & GAMBLE COMPANY (US) | 1986-05-20 | — | — | US | disclosed |
| US-4515772-A | ANTICARIES TOOTHPASTE | THE PROCTER & GAMBLE COMPANY (US) | 1985-05-07 | — | — | US | disclosed |
| EP-0097476-A2 | Oral compositions | THE PROCTER & GAMBLE COMPANY (US) | 1984-01-04 | — | — | EP | disclosed |
| US-4051234-A | BIS-GUANIDINE COMPOUND, ETHYLENEDIAMINEDIACETIC ACID OR SALT AS CHELATOR | THE PROCTER & GAMBLE COMPANY (US) | 1977-09-27 | — | — | US | disclosed |
| US-4025616-A | Oral compositions for plaque, caries and calculus retardation with reduced staining tendencies | THE PROCTER & GAMBLE COMPANY (US) | 1977-05-24 | — | — | US | disclosed |
| US-3959458-A | PHOSPHONATE OR AMINO-PHOSPHORUS COMPOUND | THE PROCTER & GAMBLE COMPANY (US) | 1976-05-25 | — | — | US | disclosed |
| US-3937807-A | BISBIGUANIDE COMPOUND | THE PROCTER & GAMBLE COMPANY (US) | 1976-02-10 | — | — | US | disclosed |
| US-3934002-A | BIS-GUANIDE | THE PROCTER & GAMBLE COMPANY (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11696879-B2 | Therapeutic dental pastes and related methods and kits | PROC, DNASE1, COL2A1 | ALDH1A1 1617/4885KDM4E 2674/4885LMNA 1536/4885 |
| US-20220211603-A1 | Oral Compositions And Methods Of Use | MSR1, GCK, TAS2R40 | ALDH1A1 4423/4885KDM4E 4231/4885LMNA 4241/4885 |
| US-20220192953-A1 | Oral Compositions And Methods Of Use | HRH2, HRH3, HRH4 | ALDH1A1 4776/4885KDM4E 3981/4885LMNA 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.